$GMED
GLOBUS MEDICAL INC Stock $gmed

$gmed Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000156276224000032 Filed on February 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$606.7M	$616.5M	$1.568B
YoY Change	119.26%	124.6%	53.34%
Cost Of Revenue	$241.5M	$265.5M	$548.2M
YoY Change	240.96%	276.09%	107.86%
Gross Profit	$365.2M	$351.0M	$1.020B
YoY Change	77.39%	72.16%	34.41%
Gross Profit Margin	60.19%	56.94%	65.05%
Selling, General & Admin	$248.7M	$244.7M	$643.4M
YoY Change	103.17%	107.26%	48.9%
% of Gross Profit	68.11%	69.71%	63.06%
Research & Development	$57.27M	$52.25M	$124.0M
YoY Change	171.64%	167.87%	69.84%
% of Gross Profit	15.68%	14.88%	12.15%
Depreciation & Amortization	$55.26M	$71.13M	$144.7M
YoY Change	205.17%	320.66%	112.06%
% of Gross Profit	15.13%	20.26%	14.19%
Operating Expenses	$357.2M	$325.1M	$887.2M
YoY Change	138.98%	128.8%	67.02%
Operating Profit	$7.997M	$25.96M	$133.1M
YoY Change	-85.82%	-58.01%	-41.59%
Interest Expense	-$17.27M	$17.33M	$34.39M
YoY Change	-357.34%	116.51%	160.27%
% of Operating Profit	-215.89%	66.76%	25.83%
Other Income/Expense, Net	-$16.56M	-$2.456M	$32.25M
YoY Change	-343.96%	-2989.41%	114.04%
Pretax Income	-$8.558M	$25.00M	$165.4M
YoY Change	-113.54%	-59.76%	-31.94%
Income Tax	-$1.441M	$9.960M	$42.52M
% Of Pretax Income		39.85%	25.71%
Net Earnings	-$7.117M	$15.04M	$122.9M
YoY Change	-114.49%	-69.97%	-35.39%
Net Earnings / Revenue	-1.17%	2.44%	7.83%
Basic Earnings Per Share	-$0.05		$1.09
Diluted Earnings Per Share	-$0.05	$0.11	$1.07
COMMON SHARES
Basic Shares Outstanding	135.4M	137.8M	113.1M
Diluted Shares Outstanding	135.4M		114.6M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$434.5M	$517.8M	$517.8M
YoY Change	-13.86%	16.08%	16.08%
Cash & Equivalents	$354.1M	$467.3M	$467.3M
Short-Term Investments	$80.41M	$50.50M	$50.50M
Other Short-Term Assets	$43.21M	$44.58M	$44.58M
YoY Change	125.04%	112.32%	112.32%
Inventory	$816.2M	$848.1M	$848.1M
Prepaid Expenses
Receivables	$534.3M	$503.2M	$503.2M
Other Receivables	$366.0K	$1.635M	$1.635M
Total Short-Term Assets	$1.829B	$1.915B	$1.915B
YoY Change	70.83%	94.78%	94.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$578.9M	$586.9M	$646.9M
YoY Change	136.19%	140.81%	165.4%
Goodwill	$1.451B	$1.435B
YoY Change	630.26%	626.46%
Intangibles	$888.2M	$924.6M
YoY Change	1400.5%	1354.37%
Long-Term Investments	$51.26M	$75.43M	$75.43M
YoY Change	-89.32%	-84.79%	-84.79%
Other Assets	$78.22M	$78.59M	$89.28M
YoY Change	73.87%	81.46%	-3.13%
Total Long-Term Assets	$3.115B	$3.171B	$3.171B
YoY Change	188.65%	190.15%	190.15%
TOTAL ASSETS
Total Short-Term Assets	$1.829B	$1.915B	$1.915B
Total Long-Term Assets	$3.115B	$3.171B	$3.171B
Total Assets	$4.944B	$5.086B	$5.086B
YoY Change	129.98%	144.98%	144.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$50.49M	$56.67M	$56.67M
YoY Change	26.74%	56.98%	56.98%
Accrued Expenses	$210.0M	$240.5M	$252.4M
YoY Change	150.02%	153.9%	166.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$424.4M	$475.0K	$475.0K
YoY Change
Total Short-Term Liabilities	$786.3M	$392.3M	$392.3M
YoY Change	369.32%	146.44%	146.44%
LONG-TERM LIABILITIES
Long-Term Debt	$298.0K	$417.4M	$417.4M
YoY Change
Other Long-Term Liabilities	$23.51M	$24.60M	$194.0M
YoY Change	75.44%	77.97%	182.04%
Total Long-Term Liabilities	$23.51M	$24.60M	$611.4M
YoY Change	75.44%	77.97%	788.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$786.3M	$392.3M	$392.3M
Total Long-Term Liabilities	$23.51M	$24.60M	$611.4M
Total Liabilities	$1.021B	$1.088B	$1.088B
YoY Change	334.95%	373.61%	373.61%
SHAREHOLDERS EQUITY
Retained Earnings	$1.047B	$1.137B
YoY Change	-18.79%	-8.28%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.922B	$3.998B	$3.998B
YoY Change
Total Liabilities & Shareholders Equity	$4.944B	$5.086B	$5.086B
YoY Change	129.98%	144.98%	144.98%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$7.117M	$15.04M	$122.9M
YoY Change	-114.49%	-69.97%	-35.39%
Depreciation, Depletion And Amortization	$55.26M	$71.13M	$144.7M
YoY Change	205.17%	320.66%	112.06%
Cash From Operating Activities	$52.39M	$104.7M	$243.5M
YoY Change	-1.74%	63.66%	36.44%
INVESTING ACTIVITIES
Capital Expenditures	$28.57M	$22.87M	$78.27M
YoY Change	78.65%	24.72%	5.71%
Acquisitions	$12.65M		$296.0M
YoY Change	375.17%		841.71%
Other Investing Activities	-$18.02M	$343.5M	$381.2M
YoY Change	-166.77%	-915.16%	-1149.82%
Cash From Investing Activities	-$46.58M	$320.6M	$303.0M
YoY Change	-523.8%	-630.0%	-374.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$225.6M
YoY Change			56.11%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-115.7M	-237.2M	-231.8M
YoY Change	-4036.09%	-1845.43%	110.82%
NET CHANGE
Cash From Operating Activities	52.39M	104.7M	243.5M
Cash From Investing Activities	-46.58M	320.6M	303.0M
Cash From Financing Activities	-115.7M	-237.2M	-231.8M
Net Change In Cash	-113.2M	188.0M	316.8M
YoY Change	-268.45%	1000.84%	-843.67%
FREE CASH FLOW
Cash From Operating Activities	$52.39M	$104.7M	$243.5M
Capital Expenditures	$28.57M	$22.87M	$78.27M
Free Cash Flow	$23.82M	$81.82M	$165.2M
YoY Change	-36.18%	79.3%	58.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001237831
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35621
CY2023	dei	Entity Registrant Name EntityRegistrantName	GLOBUS MEDICAL, INC.
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3744954
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2560 General Armistead Avenue
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Audubon
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19403
CY2023	dei	City Area Code CityAreaCode	610
CY2023	dei	Local Phone Number LocalPhoneNumber	930-1800
CY2023	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $.001 per share
CY2023	dei	Trading Symbol TradingSymbol	GMED
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4600000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	135372391
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	467292000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150466000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	50497000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	295592000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	8934000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4724000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	503235000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	213247000
CY2023Q4	us-gaap	Inventory Net InventoryNet	848135000
CY2022Q4	us-gaap	Inventory Net InventoryNet	298981000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	44580000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20997000
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	1635000
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	4061000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1915374000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	983344000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	425695000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	343036000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	586932000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	243729000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	59931000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5988000
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	75428000
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	495852000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	924603000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	63574000
CY2023Q4	us-gaap	Goodwill Goodwill	1434540000
CY2022Q4	us-gaap	Goodwill Goodwill	197471000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	78590000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37323000
CY2021	us-gaap	Revenues Revenues	958102000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	548174000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	263725000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	239223000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	10685000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	48845000
CY2023Q4	us-gaap	Assets Assets	5086083000
CY2022Q4	us-gaap	Assets Assets	2076126000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	56671000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	36101000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	240460000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92169000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11967000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2536000
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3845000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	990000
CY2023Q4	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	61035000
CY2022Q4	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	13308000
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	18369000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	14100000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	392347000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	159204000
CY2023Q4	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	78323000
CY2022Q4	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	54950000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	91037000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3475000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	417400000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	84421000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1779000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	24596000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	10345000
CY2023Q4	us-gaap	Liabilities Liabilities	1088124000
CY2022Q4	us-gaap	Liabilities Liabilities	229753000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2870749000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	630952000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10192000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24630000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1137266000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1239951000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3997959000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1846373000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5086083000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2076126000
CY2023	us-gaap	Revenues Revenues	1568476000
CY2022	us-gaap	Revenues Revenues	1022843000
CY2023	us-gaap	Gross Profit GrossProfit	1020302000
CY2022	us-gaap	Gross Profit GrossProfit	759118000
CY2021	us-gaap	Gross Profit GrossProfit	718879000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	124010000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73015000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97346000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	643410000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3818000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4673000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	432117000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	408149000
CY2023	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	434000
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2341000
CY2021	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	5921000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51032000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17735000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18526000
CY2023	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	68274000
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	5959000
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	16984000
CY2023	us-gaap	Operating Expenses OperatingExpenses	887160000
CY2022	us-gaap	Operating Expenses OperatingExpenses	531167000
CY2021	us-gaap	Operating Expenses OperatingExpenses	546926000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	133142000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	227951000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	171953000
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	20130000
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	14233000
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	9297000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	14259000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1020000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1423000
CY2023	gmed	Other Non Operating Income Expense Other OtherNonOperatingIncomeExpenseOther	-2138000
CY2022	gmed	Other Non Operating Income Expense Other OtherNonOperatingIncomeExpenseOther	1855000
CY2021	gmed	Other Non Operating Income Expense Other OtherNonOperatingIncomeExpenseOther	580000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	32251000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15068000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8454000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	165393000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	243019000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	180407000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42520000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52850000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31216000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	122873000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	190169000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	149191000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	13231000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14040000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-6054000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1207000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14438000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-17858000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-10727000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	137311000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	172311000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	138464000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.89
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.48
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.85
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.44
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	113087000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100469000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100734000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114630000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102643000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103623000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1846373000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52773000
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1925000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12396000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	11409000
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2184152000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	137311000
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	225562000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3997959000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1741388000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33466000
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1985000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41715000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	172311000
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	144493000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1846373000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1506297000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31254000
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1878000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	63496000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	138464000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1741388000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	122873000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	190169000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	149191000
CY2022	gmed	Acquired Research And Development In Process AcquiredResearchAndDevelopmentInProcess	150000
CY2021	gmed	Acquired Research And Development In Process AcquiredResearchAndDevelopmentInProcess	34312000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	144733000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	68252000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69867000
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-793000
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-5389000
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-2781000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	10959000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	6400000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	6143000
CY2023	gmed	Amortization Of Inventory Fair Value Step Up AmortizationOfInventoryFairValueStepUp	71656000
CY2023	gmed	Amortization Of Note Fair Value Step Up AmortizationOfNoteFairValueStepUp	8176000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	52742000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	32810000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	30586000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3658000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1200000
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	17434000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5132000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	16807000
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-57789000
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-22223000
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-17615000
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1541000
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-299000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-464000
CY2023	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	3005000
CY2022	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	2647000
CY2021	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	210000
CY2023	gmed	Net Gain Loss From Foreign Currency Adjustment NetGainLossFromForeignCurrencyAdjustment	-13674000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	49914000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	50843000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25895000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	70328000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	61745000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11971000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1148000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10292000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6178000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-14223000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	14418000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3684000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	17127000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6087000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	17896000
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-408000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2887000
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5212000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	243499000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	178468000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	276274000
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	100643000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	419534000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	622359000
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	240190000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	312221000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	227908000
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	537723000
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	102433000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	109898000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	78274000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74047000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56898000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	296028000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	31435000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	34488000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	302968000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-110362000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-375939000
CY2023	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	8039000
CY2022	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	7185000
CY2021	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	9349000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12397000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	41716000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	63496000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	10617000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	225562000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	144493000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-231821000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-109962000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54147000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2180000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-747000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-810000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	316826000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42603000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46328000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150466000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193069000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	239397000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	467292000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150466000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193069000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	100593000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	77823000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	45027000
CY2023	us-gaap	Stock Issued1 StockIssued1	2153860000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7100000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7423000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4551000
CY2023	gmed	Number Of Products Launched During Period NumberOfProductsLaunchedDuringPeriod	10
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Prior Period Reclassifications</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Certain prior period amounts have been reclassified to conform to the current period presentation. “Operating lease right of use assets” were reclassified out of “Other assets”, and “Operating lease liabilities” were reclassified out of “Accrued expenses” and “Other liabilities”, respectively, depending on the short-term and long-term nature, on our consolidated balance sheets.</span>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Significant areas that require estimates include revenue recognition, intangible assets, business acquisition liabilities, allowance for doubtful accounts, stock-based compensation, reserves for excess and obsolete inventory, fair value measurements, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Concentrations of Credit Risk</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments, which potentially subject us to concentrations of credit risk, are primarily marketable securities and accounts receivable. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of entities comprising our customer base. We perform ongoing credit evaluations of our customers and generally do not require collateral.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">There was </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">no</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> customer that accounted for 10% or more of sales for the years ended </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">December 31, 2023, 2022, and 2021</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">, respectively.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p>
CY2021	gmed	Number Of Customers That Accounted For10 Or More Of Sales NumberOfCustomersThatAccountedFor10OrMoreOfSales	0
CY2022	gmed	Number Of Customers That Accounted For10 Or More Of Sales NumberOfCustomersThatAccountedFor10OrMoreOfSales	0
CY2023	gmed	Number Of Customers That Accounted For10 Or More Of Sales NumberOfCustomersThatAccountedFor10OrMoreOfSales	0
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Revenues Revenues	1568476000
CY2022	us-gaap	Revenues Revenues	1022843000
CY2021	us-gaap	Revenues Revenues	958102000
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	51630000
CY2023Q4	gmed	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	1133000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	50497000
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	76749000
CY2023Q4	gmed	Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax	1321000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	75428000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	301338000
CY2022Q4	gmed	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	12000
CY2022Q4	gmed	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	5758000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	295592000
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	509892000
CY2022Q4	gmed	Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax	351000
CY2022Q4	gmed	Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax	14391000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	495852000
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	203689000
CY2023Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	417363000
CY2023Q4	gmed	Bifurcated Convertible Option On Convertible Debt BifurcatedConvertibleOptionOnConvertibleDebt	687000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	139358000
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	17655000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	68258000
CY2023	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	14100000
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1000000.0
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	103349000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	60324000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	37321000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	18699000
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	707465000
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	219958000
CY2023Q4	us-gaap	Inventory Net InventoryNet	848135000
CY2022Q4	us-gaap	Inventory Net InventoryNet	298981000
CY2023	gmed	Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory	10900000
CY2022	gmed	Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory	6400000
CY2021	gmed	Net Adjustment To Cost Of Sales Related To Excess And Obsolete Inventory NetAdjustmentToCostOfSalesRelatedToExcessAndObsoleteInventory	6100000
CY2023	gmed	Excess And Obsolete Related Provisions ExcessAndObsoleteRelatedProvisions	18100000
CY2022	gmed	Excess And Obsolete Related Provisions ExcessAndObsoleteRelatedProvisions	18500000
CY2021	gmed	Excess And Obsolete Related Provisions ExcessAndObsoleteRelatedProvisions	20200000
CY2023	gmed	Inventory Sales And Disposals Related Provisions InventorySalesAndDisposalsRelatedProvisions	7200000
CY2022	gmed	Inventory Sales And Disposals Related Provisions InventorySalesAndDisposalsRelatedProvisions	12100000
CY2021	gmed	Inventory Sales And Disposals Related Provisions InventorySalesAndDisposalsRelatedProvisions	14100000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1012627000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	586765000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	425695000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	343036000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	586932000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	243729000
CY2023	us-gaap	Depreciation Depreciation	93702000
CY2022	us-gaap	Depreciation Depreciation	50517000
CY2021	us-gaap	Depreciation Depreciation	51342000
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2174000
CY2021Q4	us-gaap	Goodwill Goodwill	179708000
CY2022	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	18799000
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1036000
CY2022Q4	us-gaap	Goodwill Goodwill	197471000
CY2023	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	1235890000
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1179000
CY2023Q4	us-gaap	Goodwill Goodwill	1434540000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1062341000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	137738000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	924603000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	150296000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	86722000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	63574000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	118084000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	113798000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	110354000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	109249000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	105783000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	367336000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	924603000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	140817000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	53352000
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2889000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114630000
CY2023Q4	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	9335000
CY2022Q4	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	5564000
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	23726000
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	10029000
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	10130000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4375000
CY2023Q4	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	27605000
CY2022Q4	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	10501000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	28847000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8348000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	240460000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	92169000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	122873000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	190169000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	149191000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	122873000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	190169000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	149191000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	113087000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100469000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100734000
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1543000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102643000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103623000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.89
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.48
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.07
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.85
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.44
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13531000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3851000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2139000
CY2023Q4	gmed	Share Based Compensation Number Of Stock Plans ShareBasedCompensationNumberOfStockPlans	4
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10338000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	51.86
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1897000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	57.51
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	387000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	32.31
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	447000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	62.92
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11401000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	53.02
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	61489000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7103000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	49.20
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M18D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	52537000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4292000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	59.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	8952000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10800000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	26300000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	71300000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0345
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0477
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0146
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0404
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0040
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0114
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.350
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.380
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.330
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.350
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.330
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.340
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38995000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32810000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30586000
CY2023	gmed	Stock Based Compensation Expense Classified In Acquisition Related Costs StockBasedCompensationExpenseClassifiedInAcquisitionRelatedCosts	13747000
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	31000
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	657000
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	667000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	52773000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	33467000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	31253000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	181752000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	247260000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	184819000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-16359000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4241000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4412000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	165393000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	243019000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	180407000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	81504000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	60927000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	37436000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	15190000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	12408000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7688000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4075000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1845000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3741000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	100769000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	75180000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	48865000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-46217000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-16429000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-13535000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-6421000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3142000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2265000
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-5611000
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2759000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1849000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-58249000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22330000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-17649000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42520000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52850000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31216000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.030
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.027
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.016
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.034
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.013
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.015
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.012
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.066
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.013
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.005
CY2023	gmed	Effective Income Tax Rate Reconciliation Foreign Inclusions EffectiveIncomeTaxRateReconciliationForeignInclusions	-0.009
CY2023	gmed	Effective Income Tax Rate Reconciliation Acquisition Related Charges EffectiveIncomeTaxRateReconciliationAcquisitionRelatedCharges	0.049
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.257
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.217
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.173
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	27228000
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	29649000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	37798000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	27608000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	39715000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	20554000
CY2023Q4	gmed	Deferred Tax Assets Capitalized Re DeferredTaxAssetsCapitalizedRE	68832000
CY2022Q4	gmed	Deferred Tax Assets Capitalized Re DeferredTaxAssetsCapitalizedRE	14279000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	128810000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	4182000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	42569000
CY2023Q4	gmed	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	22887000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	30948000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	398787000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	96272000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	190762000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5488000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	208025000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	90784000
CY2023Q4	gmed	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	244348000
CY2022Q4	gmed	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	43718000
CY2023Q4	gmed	Right Of Use Asset RightOfUseAsset	-12370000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	256718000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	43718000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	48693000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	47066000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	190800000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5500000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	986000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1052000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1600000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	853000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	32045000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	50000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	160000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	127000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	116000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	708000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	33757000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	986000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1052000
CY2023	gmed	Additions Related To Current Year Tax Positions AdditionsRelatedToCurrentYearTaxPositions	900000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	32000000.0
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	100000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	27601000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1355000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1471000
CY2023	gmed	Lease Term That Are Not Recognized As Right Of Use Assets Or Lease Liabilities LeaseTermThatAreNotRecognizedAsRightOfUseAssetsOrLeaseLiabilities	P12M
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	1500000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	59931000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5988000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	797000
CY2023Q4	gmed	Total Leased Assets TotalLeasedAssets	60728000
CY2022Q4	gmed	Total Leased Assets TotalLeasedAssets	5988000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11967000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2536000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	475000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	91037000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3475000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	337000
CY2023Q4	gmed	Total Lease Liability TotalLeaseLiability	103816000
CY2022Q4	gmed	Total Lease Liability TotalLeaseLiability	6011000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	19471000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2588000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	903000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	67000
CY2023	us-gaap	Lease Cost LeaseCost	20441000
CY2022	us-gaap	Lease Cost LeaseCost	2588000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	498000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	18336000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	182000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14931000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	170000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13431000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12352000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	11281000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	74018000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	850000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	144350000
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	38000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	41346000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	812000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	103004000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	475000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11967000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	337000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	91037000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	19773000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2545000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1743000
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	67000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	913000
CY2023	gmed	Total Cash Paid For Amounts Included In Measurement Of Lease Liabilities TotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	20753000
CY2022	gmed	Total Cash Paid For Amounts Included In Measurement Of Lease Liabilities TotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	2545000
CY2021	gmed	Total Cash Paid For Amounts Included In Measurement Of Lease Liabilities TotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	1743000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9043000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1915000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1436000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P14Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.035
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.027
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.044
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	10525000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	7154000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6588000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Revenues Revenues	1568476000
CY2022	us-gaap	Revenues Revenues	1022843000
CY2021	us-gaap	Revenues Revenues	958102000
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	586932000
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	243729000
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2023	dei	Auditor Firm AuditorFirmId	34

Files In Submission

Name	View Source	Status
0001562762-24-000032-index-headers.html	Edgar Link	pending
0001562762-24-000032-index.html	Edgar Link	pending
0001562762-24-000032.txt	Edgar Link	pending
0001562762-24-000032-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gmed-20231231.xsd	Edgar Link	pending
gmed-20231231x10k.htm	Edgar Link	pending
gmed-20231231x10kg001.jpg	Edgar Link	pending
gmed-20231231xex21_1.htm	Edgar Link	pending
gmed-20231231xex23_1.htm	Edgar Link	pending
gmed-20231231xex31_1.htm	Edgar Link	pending
gmed-20231231xex31_2.htm	Edgar Link	pending
gmed-20231231xex32.htm	Edgar Link	pending
gmed-20231231xex4_2.htm	Edgar Link	pending
gmed-20231231xex97_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gmed-20231231_cal.xml	Edgar Link	unprocessable
gmed-20231231x10k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
gmed-20231231_pre.xml	Edgar Link	unprocessable
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
gmed-20231231_def.xml	Edgar Link	unprocessable
gmed-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GMED
GLOBUS MEDICAL INC Stock $gmed

2024 Q1 Form 10-K Financial Statement

#000156276224000032 Filed on February 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED GLOBUS MEDICAL INC Stock $gmed

2024 Q1 Form 10-K Financial Statement

#000156276224000032 Filed on February 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED
GLOBUS MEDICAL INC Stock $gmed